Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 Holdings, Inc. (Nasdaq: SNCE) is a pioneering company based in Los Angeles that specializes in accelerating biomedical discovery through innovative, patient-centric clinical research models. Utilizing cutting-edge telemedicine technology, Science 37 offers a comprehensive range of services for conducting networked clinical trials, making it an invaluable partner for investigators, inventors, biotech firms, and large pharmaceutical companies.
At the core of Science 37's operations is the Metasite™, a proprietary virtual site platform that allows patients to participate in clinical trials from the comfort of their own homes or local healthcare providers. Powered by in-house medical and operational experts, the Metasite™ ensures uniform study orchestration, greater compliance, and high-quality data, thereby making clinical trials more accessible and efficient.
Science 37 leverages a vast network of partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups, and technology companies to streamline the clinical trial process. The company's recent achievements include the successful completion of a reverse stock split and a partnership with leading telemedicine companies, which has significantly expanded its reach and capabilities.
Noteworthy recent developments include the approval of a reverse stock split to comply with Nasdaq listing requirements and the commencement of a cash tender offer by eMed to purchase all outstanding shares of Science 37 at $5.75 per share. This move, coupled with the company's continuous efforts in enhancing patient recruitment through AI-powered screening and centralized processes, underscores its commitment to innovation and operational excellence.
Science 37 has also been recognized for its transformative impact on clinical research, winning the “Clinical Efficiency Innovation Award” at the 8th annual MedTech Breakthrough Awards. This award highlights the company's unique approach to patient recruitment, which has significantly improved patient randomization rates and site satisfaction.
For more detailed information and to stay updated on the latest developments, please visit Science 37's website.
Science 37 Holdings, Inc. (SNCE) reported robust financial results for Q4 and full year 2021, with revenue rising 83% to $20.4 million in Q4 and 151% to $59.6 million for the year. Net bookings also surged, achieving 102% growth for the quarter at $43.2 million and 194% annual growth at $163.9 million. However, the company recorded a net loss of $65.1 million in Q4 and $94.3 million for the year. Looking forward, Science 37 anticipates revenue between $86 and $96 million for 2022, signaling confidence in continued growth.
Science 37 Holdings, Inc. (Nasdaq: SNCE) will announce its fourth quarter and full year 2021 financial results on March 22, 2022, before market open. A conference call will follow at 5:00 a.m. PT / 8:00 a.m. ET, accessible by dialing (844) 467-7754 for domestic callers and (270) 215-9366 for international participants. Investors can view a live and archived webcast on the Science 37 Investor Relations website. The company aims to enhance patient access to clinical research through its Agile Clinical Trial Operating System, which promotes faster enrollment and diverse patient populations.
Science 37 Holdings, Inc. (Nasdaq: SNCE) announced its participation in the Cowen 42nd Annual Health Care Conference, scheduled for March 7, 2022, at 1:30 p.m. Eastern Time. The presentation will be accessible via a live and archived webcast on the company’s Investor Relations website. Science 37 aims to improve access to clinical trials through its Agile Clinical Trial Operating System, which supports diverse patient populations and faster enrollment rates. The company focuses on decentralized trials to enhance efficiencies in clinical research.
Science 37 Holdings, Inc. (Nasdaq: SNCE) significantly expanded its clinical trial network, adding nearly 35,000 physician-providers since January 2021, which enhances agile trial execution.
By contracting with over 800 healthcare organizations, the company now has access to 28 million patients globally. This expansion aims to reduce the infrastructure barriers for physician participation in clinical trials, allowing for patient enrollment up to 15 times faster than traditional methods, and the potential to conduct more complex studies.
Science 37 Holdings (Nasdaq: SNCE) has partnered with physIQ to enhance digital clinical trials using remote biosensors and machine learning. The collaboration aims to create predictive digital biomarkers that assist in demonstrating treatment safety and efficacy. With physIQ's established FDA-approved platform and capabilities in processing real-time biosensor data, this partnership is expected to strengthen Science 37's Agile Clinical Trial Operating System, facilitating faster trial results and improved patient monitoring.
Science 37 and Worldwide Clinical Trials have announced a strategic collaboration aimed at enhancing decentralized clinical trial delivery. This partnership leverages Science 37's Agile Clinical Trial Operating System to improve patient participation and streamline processes. By localizing patient visits, the collaboration seeks to expedite enrollment, boost retention rates, and ensure a more representative patient demographic. Both organizations aim to address challenges in clinical trials across various therapeutic areas such as oncology and neurology, facilitating a hybrid approach to enhance study timelines.
Science 37 has enhanced its Operating Systems, enabling deployment of its technology platform into China and Russia. This advancement allows for further penetration into the Asia-Pacific market, facilitating global decentralized clinical trials. The company aims to improve enrollment speed and patient retention, delivering trials in nearly 95 countries across 45 languages. With this upgrade, Science 37 continues to provide flexible and accessible clinical research, vital for developing treatments that can positively affect patients' lives.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has revealed a significant industry shift towards agile and hybrid clinical trials. A recent sentiment study of 127 senior executives indicates that nearly 80% plan to conduct agile trials in 2022, compared to 70% for traditional methods. Oncology is expected to see the highest adoption of decentralized clinical trials (DCT), with 46% of respondents anticipating DCT usage. The study identifies key benefits including increased patient retention and faster recruitment, while also highlighting integration and regulatory challenges.
FAQ
What is the market cap of Science 37 Holdings (SNCE)?
What does Science 37 Holdings, Inc. specialize in?
What is the Metasite™?
What recent financial developments have occurred at Science 37?
What awards has Science 37 won recently?
How does Science 37 enhance patient recruitment for clinical trials?
Who are Science 37's main partners?
Where is Science 37 headquartered?
What is the aim of Science 37's clinical research models?
What is the significance of the reverse stock split for Science 37?
How can I learn more about Science 37's active studies?
